Purui Biotech Secures Tens of Millions in RMB Financing Led by YUEIN Healthcare Fund to Advance PDTX® Clinical Applications and Files IPO Prospectus
VCBeat (WeChat ID: vcbeat) has learned that recently, China's leadingPersonalized Diagnosis and Treatment of TumorsNanjing Pu Enrui Biological Technology Co., Ltd. Officially Announces Completion of Tens of Millions of RMB in FinancingNanjing Pu Enrui Biological Technology Co., Ltd. has officially announced the completion of a financing round amounting to tens of millions of RMB. Professional investment institutions, including Yueyin Medical Fund and Puhua Capital, participated as investors in this round. The funds raised will be primarily allocated to new product research and development, as well as the establishment of international multi-center clinical trials.
A review of the outstanding companies previously invested in by Yueyin Medical Fund—including Kaipu Imaging, Zhenluo Technology, Genetron Health, Daka Zhuyun, Mingyi Zhudao, The Lancet Doctors, Shuchuang Robotics, and Meiermu Eye Hospital—reveals that they all adhere to the same logic of “focusing on specialization.”
Cancer statistics released by the National Cancer Center show that in 2015, there were 4.291 million new cancer cases and 2.814 million cancer-related deaths in China, equivalent to an average of 12,000 new cancer diagnoses and 7,500 cancer deaths per day. Malignant tumors exhibit significant inter-individual variability, and traditional standard treatment regimens fail to provide precise therapy for each patient. In conventional tumor and cancer treatments, the inefficacy rate of medication reaches as high as 75% (WIN Symposium 2016), causing severe physical harm to patients and resulting in substantial waste of medical resources (such as hospitalization costs and management of toxic side effects).
Pu Enrui Biological Technology, established in 2015, is the first research institution in China dedicated to personalized tumor diagnosis and treatment through in vivo pharmacodynamic testing. After three years of development, Pu Enrui Biological Technology has, through PDTX® Continuous improvement of detection technology, holding multiple PDTX® patents, mastering core technologies across the entire value chain, and has currently become a leading domesticPDTX® The company with the largest scale of clinical application, the most extensive data accumulation, and the strongest technology.
PDTX National Mouse Resource Bank
Currently, Pu Enrui PDTX® The modeling success rate has reached 80%, and the detection time has been reduced from 4–6 months internationally to 2–4 months, marking a significant breakthrough in pharmacodynamic drug testing. This advancement has resolved critical issues such as the conversion of murine dosages to clinical doses, thereby greatly enhancing the clinical application value and practical guiding significance of PDTX®. The company’s detection technology has reached a world-class level. It not only achieves successful transplantation of surgical tissue samples but also enables successful modeling using small tumor tissue samples obtained through various methods, including needle biopsy and endoscopic biopsy. As a result, the company has become the only one in China to master small-sample modeling technology.
Chief Scientist, Professor Chen Duan, Member of the Norwegian Academy of Technological Sciences
In May 2017, Professor Duan Chen, a globally renowned expert in molecular medicine and Academician, joined the company as Chief Scientist. Professor Chen is an Academician of the Norwegian Academy of Technological Sciences, a Tenured Professor in the Department of Clinical and Molecular Medicine at the Norwegian University of Science and Technology (NTNU), and Chair of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR). He was the first to propose the developmental mechanisms of gastrointestinal tumors and the theory of “neuron-cancer cell interactions within the tumor microenvironment” on the international stage.
Regarding this round of investment, Ms. Zheng Yufen, Managing Partner of Yueyin Medical Fund, candidly stated, “As an investment institution focused on the healthcare industry, we have invested in nearly 20 leading medical enterprises across various specialized sectors. Personalized precision diagnosis and treatment for cancer patients hold immense social and market value. There are currently approximately 7.5 million cancer patients in China, with a five-year survival rate less than half that of the United States. With the continued maturation and market adoption of PDTX technology, the domestic PDTX market size is projected to reach RMB 70 billion. The company has completed nearly 500 clinical cases in Beijing, Shanghai, Tianjin, Nanjing, and Hangzhou, accumulating close to 7,000 drug efficacy models.”The only company in China with a clinical phenotype–pharmacodynamic phenotype–molecular phenotype life omics database, its future potential and value are promising, and we are full of confidence in the company."
Ms. Zhu Yanping, the company’s founder, stated, “The company has remained dedicated to research and exploration in the field of PDTX®, with the aim of establishing standardized and widespread clinical application of PDTX® in China. We strive to identify the most appropriate therapeutic approaches for diseases and provide tangible, effective support to more oncology patients and physicians. While actively advancing the commercial clinical application of PDTX®, Nanjing Pu Enrui Biological Technology Co., Ltd. is also leveraging its robust oncology database and live tissue biobank to continuously explore new product development in areas such as PDTX®-based diagnostic kits, data chips, and humanized antibodies. Over the next two years, the company will launch multiple precision oncology diagnosis and treatment products for sale, and we are filled with anticipation for the future.”